Benchmarking the Pharma Industry’s HEOR Functions


Looking for our most recent market research report on this topic? Click here.

This report provides pharmaceutical and biotech organizations an opportunity to benchmark their own Health Economics and Outcomes Research (HEOR) approaches against that of Top 50 Pharma companies.

ISR details best practices, common approaches, as well as explains alternative styles so companies can use these assessments as a yard stick against which to measure, modify, and improve their own HEOR structures.

HQ and regional structuring models

  • Headcount
  • Organizational alignment with Medical Affairs, R&D, and Market Access
  • Division of work
  • Headquarters vs. in-country affiliates
  • “Centers of Excellence”
  • Involvement in pricing and reimbursement
  • Outsourcing and vendor selection
  • Annual product budgets
  • Challenges
  • Future Predictions
  • Best Practices
  • Recommendations

Qualities of successful HEOR employees, as well as professional development and group structuring strategies to improve HEOR functional effectiveness

Ways to optimize HEOR work to avoid clinical development delays by identifying barriers and understanding ideal timing of HEOR project kickoff, design, and execution

  • Learn from on-the-ground professionals to develop successful and timely HEOR programs that seamlessly integrate with Research & Development to establish a persuasive product narrative
  • Benchmark the structuring of HEOR resources against Top 50 Pharma to optimize group effectiveness and improve resource development
  • Identify best practices, recommendations, and challenges for all aspects of HEOR as described by 1 Vice President, 15 Directors, and 1 Group Manager within Top 50 Pharma

1. Understanding the HEOR Function

  • HEOR Employees
  • HEOR Work

2. HEOR Department Benchmarking

  • Division of Work
  • Department Structure
  • Organizational Alignment
  • Outsourcing
  • Product Budgets

ISR interviewed 17 senior employees with decision-making responsibilities in HEOR departments among the top 50 largest pharmaceutical companies. Pharma company rankings were determined by the “2013 Pharm Exec Top 50” pharmaceutical companies based on 2012 Rx Sales.

  • Global HEOR headquarters respondents: 13
  • Regional headquarters or country affiliate respondents: 4

The titles below are held by our interviewees:

  • Vice President, Global HEOR
  • Director, Global HEOR (4)
  • Director, Global Health Outcomes
  • Director, Global Health Economics and Market Access
  • Director, HEOR (4)
  • Group Director, Global HEOR
  • Associate Director, HEOR (2)
  • Deputy Director, Global HEOR
  • Director, Public Policy and HEOR
  • Group Manager, Health Economics

ISR understands that you’re looking for confidence in your market research. With ISR, you’ll consistently receive

  • Focused Domain Expertise — We’ve operated in pharmaceuticals for over 15 years and because it’s our sole focus, our domain expertise brings value to the work that “generalist” researchers can’t deliver.
  • Genuine Research Expertise — Our market research experience has developed over 20 years in many dynamic industries.  We capture appropriate sample sizes, given the research objectives, and we use appropriately sophisticated statistics to uncover everything that’s real and to give you confidence in your decisions. Read our Six Questions to Ask About Your Market Research to learn more about why our industry expertise sets us apart.
  • Transparency — If you’re like many, you’ve been disappointed more than once by research providers who fail to live up to their promises, providing you with their “professional judgment” in place of sound data; and suspect contacts instead of real decision-makers. We deliver the beliefs, attitudes, and intentions of people who matter – and we’ll prove it by showing you the titles of your respondents.

For additional questions about any of ISR’s reports or custom research services, please contact us at

Additional information


, ,


There are no reviews yet.

Be the first to review “Benchmarking the Pharma Industry’s HEOR Functions”